Cargando…

Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) is easily degraded by dipeptidyl peptidase-4 (DPP-4) in the human body, limiting its therapeutic effect on type II diabetes. Therefore, improving GLP-1 receptor agonist (GLP-1RA) stability is a major obstacle for drug development. We analyzed human GLP-1, DPP-4, and G...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Lei, Zheng, Zhi-Ming, Shao, Chang-Sheng, Zhang, Zhi-Yong, Li, Ming-Wei, Wang, Li, Wang, Han, Zhao, Gen-Hai, Wang, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230455/ https://www.ncbi.nlm.nih.gov/pubmed/35745659 http://dx.doi.org/10.3390/ph15060740

Ejemplares similares

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update
por: Vandemark, Collin, et al.
Publicado: (2023)

A potentially serious adverse effect of GLP-1 receptor agonists
por: Lu, Jinmiao, et al.
Publicado: (2023)

Recombinant Expression and Stapling of a Novel Long-Acting GLP-1R Peptide Agonist
por: Lear, Sam, et al.
Publicado: (2020)

Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc
por: Yang, Yi, et al.
Publicado: (2016)

A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
por: Al-Zamel, Noura, et al.
Publicado: (2019)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
por: Wang, Lijing
Publicado: (2022)

Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy
por: McCrimmon, Rory J., et al.
Publicado: (2021)

The Rational Design and Biological Mechanisms of Nanoradiosensitizers
por: Sun, Hainan, et al.
Publicado: (2020)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance
por: Cacciatori, Vittorio, et al.
Publicado: (2017)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Tropical Plant Extracts as Potential Antihyperglycemic Agents
por: Manaharan, Thamilvaani, et al.
Publicado: (2012)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Clinical Trial Highlights – GLP-1 agonists
por: McFarthing, Kevin, et al.
Publicado: (2020)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

ODP259 Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonist in T1DM Patients
por: Mohandas, Deene, et al.
Publicado: (2022)

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
por: Wang, Jing-Yue, et al.
Publicado: (2023)

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists
por: Urva, Shweta, et al.
Publicado: (2020)

The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile
por: Larsen, Anna Thorsø, et al.
Publicado: (2021)

Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4
por: Tinsley, Ian C., et al.
Publicado: (2021)

Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis
por: Song, Nazi, et al.
Publicado: (2022)

Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects
por: Zhong, Xia, et al.
Publicado: (2019)

GLP-1 receptor agonist as a modulator of innate immunity
por: Chen, Jun, et al.
Publicado: (2022)

PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments
por: Veliceasa, Dorina, et al.
Publicado: (2008)

A rationally designed JAZ subtype-selective agonist of jasmonate perception
por: Takaoka, Yousuke, et al.
Publicado: (2018)

Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists
por: Alharbi, Arwaf S, et al.
Publicado: (2020)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

Design, Synthesis and in Vivo Evaluation of Novel Glycosylated Sulfonylureas as Antihyperglycemic Agents
por: Suaifan, Ghadeer A. R. Y., et al.
Publicado: (2015)

An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke
por: Zhang, Huinan, et al.
Publicado: (2016)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
por: Chudleigh, Richard A, et al.
Publicado: (2020)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
por: Xu, Dan, et al.
Publicado: (2022)

Rational Design and Biological Application of Antioxidant Nanozymes
por: Tian, Ruizhen, et al.
Publicado: (2021)

Designing and computational analyzing of chimeric long-lasting GLP-1 receptor agonists for type 2 diabetes
por: Ehsasatvatan, Maryam, et al.
Publicado: (2023)

The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice
por: Li, Ping-Chia, et al.
Publicado: (2016)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pgo0epnhf0i5hi1b7m69s6vfua